ITIF Search

Bayh-Dole and the Coronavirus Crisis

Bayh-Dole and the Coronavirus Crisis
Thursday, April 23, 202012:30 PM to 1:45 PM EST
Video Webinar

Event Summary

The world is anxiously awaiting effective treatments for COVID-19, which is ravaging most countries. Fortunately, some of the best minds in our public and private sectors are putting everything they have into developing effective vaccines, drugs, and tests that are so desperately needed. Because of the Bayh-Dole Act, which allows academic institutions and federal laboratories to effectively license their discoveries so they can make the leap from being laboratory concepts into useful products, these partnerships are proceeding at full speed. Unfortunately, some want to undo this model at the very time we need it the most.

ITIF and the Bayh-Dole 40 Coalition hosted a video webinar delving into the critical role that partnerships between industry, academia, and federal labs will play in combating COVID-19, how these partnerships work, what risks they entail, why patents and licenses are so important in overcoming the risks inherent in developing drugs and vaccines, and how the Bayh-Dole Act enables the process for the benefit of people in the United States and around the world.

Follow @ITIFdc on Twitter.


Stephen Ezell@sjezell
Vice President, Global Innovation Policy, and Director, Center for Life Sciences Innovation
Information Technology and Innovation Foundation
Joseph Allen
Former President
National Technology Transfer Center
Wendy Commins Holman
Chief Executive Officer and Founder
Ridgeback Biotherapeutics
Mark Rohrbaugh
Special Advisor for Technology Transfer
National Institute of Health
Jon Soderstrom
Managing Director
University Technology Commercialization and Faculty Innovation, Yale University
Back to Top